Pulse Biosciences (NASDAQ:PLSE) Issues Earnings Results, Beats Estimates By $0.04 EPS

Pulse Biosciences (NASDAQ:PLSE) announced its quarterly earnings data on Thursday. The company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.04, Fidelity Earnings reports.

PLSE traded up $0.08 on Friday, reaching $14.39. 63,300 shares of the company traded hands, compared to its average volume of 56,101. The company has a market cap of $306.54 million, a price-to-earnings ratio of -6.54 and a beta of 1.84. Pulse Biosciences has a 52-week low of $9.52 and a 52-week high of $19.77. The stock’s 50 day moving average price is $14.95 and its 200-day moving average price is $13.25. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.92 and a quick ratio of 12.92.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of research analysts recently commented on the stock. ValuEngine raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, October 30th. BidaskClub downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.

See Also: What is a SEC Filing?

Earnings History for Pulse Biosciences (NASDAQ:PLSE)

Leave a Reply

Your email address will not be published. Required fields are marked *